Combination of dasabuvir and PSI-6206 for the treatment of coxsackievirus B3 infection

Coxsackievirus B3 (CVB3) infections may cause life-threatening diseases and have no approved specific treatment. Some promising approaches to treat viral diseases include drug repurposing and combination therapy. We have selected in this study dasabuvir, an approved antiviral drug, and PSI-6206, an...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Virus Eradication 2022-06, Vol.8 (2), p.100074
Main Authors: Olasunkanmi, Oluwatayo Israel, Zhong, Zhao-Hua
Format: Article
Language:English
Subjects:
Coxsackievirus B3
Dasabuvir
Drug combination
Drug repurposing
Original Research
PSI-6206
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coxsackievirus B3 (CVB3) infections may cause life-threatening diseases and have no approved specific treatment. Some promising approaches to treat viral diseases include drug repurposing and combination therapy. We have selected in this study dasabuvir, an approved antiviral drug, and PSI-6206, an experimental drug and determined their individual and combined antiviral activity against CVB3 replication in vitro . Our results show that the individual drugs inhibited CVB3 infection in a dose-dependent manner, at a selective index >10 with a strong synergetic antiviral effect of the two compounds. Given that dasabuvir has already been approved for the treatment of hepatitis C virus infection, treatment of CVB3-related disease with this drug may represent a promising treatment strategy.
ISSN:2055-6640
2055-6659
DOI:10.1016/j.jve.2022.100074